However, as our dose regimen is considered acute treatment, it is also unlikely that the action of CCKAR antagonists in reducing AHR in our mouse models was through inhibition of proliferation of asthma-relevant cells such as bronchial epithelial cells. The gene discussed is AHR; the disease is asthma.